Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 8/2013

01-08-2013 | Original Article

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK

Authors: Carol Inatsuka, Yi Yang, Ekram Gad, Lauren Rastetter, Mary L. Disis, Hailing Lu

Published in: Cancer Immunology, Immunotherapy | Issue 8/2013

Login to get access

Abstract

Polysaccharide K (PSK) is a widely used mushroom extract that has shown anti-tumor and immunomodulatory effects in both preclinical and clinical studies. Therefore, it is important to understand the mechanism of actions of PSK. We recently reported that PSK can activate toll-like receptor 2 and enhances the function of NK cells. The current study was undertaken to study the effect of PSK on gamma delta (γδ) T cells, another important arm of the innate immunity. In vitro experiments using mouse splenocytes showed that γδ T cells produce IFN-γ after treatment with PSK and have up-regulated expression of CD25, CD69, and CD107a. To investigate whether the effect of PSK on γδ T cells is direct or indirect, purified γδ T cells were cultured either alone or together with bone marrow-derived DC in a co-culture or trans-well system and then stimulated with PSK. Results showed that direct cell-to-cell contact between γδ T cells and DC is required for optimal activation of γδ T cells. There was also reciprocal activation of DC by PSK-activated γδ T cells, as demonstrated by higher expression of costimulatory molecules and enhanced production of IL-12 by DC in the presence of γδ T cells. PSK can also co-stimulate γδ T cells with anti-TCR and anti-CD3 stimulation, in the absence of DC. Finally, in vivo treatment with PSK activates γδ T cells among the tumor infiltrating lymphocytes, and depleting γδ T cells during PSK treatment attenuated the anti-tumor effect of PSK. All together, these results demonstrated that γδ T cells are activated by PSK and contribute to the anti-tumor effect of PSK.
Appendix
Available only for authorised users
Literature
3.
4.
go back to reference Kidd PM (2000) The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5:4–27PubMed Kidd PM (2000) The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5:4–27PubMed
5.
go back to reference Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22:1737–1754PubMed Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22:1737–1754PubMed
6.
go back to reference Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411PubMedCrossRef Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411PubMedCrossRef
8.
go back to reference Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67:5–8PubMedCrossRef Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67:5–8PubMedCrossRef
9.
go back to reference Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879–6884PubMedCrossRef Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879–6884PubMedCrossRef
11.
go back to reference Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD (2008) Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180:6044–6053PubMed Liu Z, Eltoum IE, Guo B, Beck BH, Cloud GA, Lopez RD (2008) Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 180:6044–6053PubMed
12.
13.
go back to reference Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56:469–476. doi:10.1007/s00262-006-0199-6 PubMedCrossRef Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H (2007) Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 56:469–476. doi:10.​1007/​s00262-006-0199-6 PubMedCrossRef
14.
go back to reference Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786. doi:10.1038/bjc.2011.293 PubMedCrossRef Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786. doi:10.​1038/​bjc.​2011.​293 PubMedCrossRef
15.
go back to reference Lopez RD, Xu S, Guo B, Negrin RS, Waller EK (2000) CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96:3827–3837PubMed Lopez RD, Xu S, Guo B, Negrin RS, Waller EK (2000) CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96:3827–3837PubMed
17.
go back to reference Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma}delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450–7457PubMedCrossRef Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma}delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450–7457PubMedCrossRef
18.
go back to reference Beck BH, Kim HG, Kim H, Samuel S, Liu Z, Shrestha R, Haines H, Zinn K, Lopez RD (2010) Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat 122:135–144. doi:10.1007/s10549-009-0527-6 PubMedCrossRef Beck BH, Kim HG, Kim H, Samuel S, Liu Z, Shrestha R, Haines H, Zinn K, Lopez RD (2010) Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat 122:135–144. doi:10.​1007/​s10549-009-0527-6 PubMedCrossRef
21.
go back to reference Lu H, Knutson KL, Gad E, Disis ML (2006) The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res 66:9754–9761PubMedCrossRef Lu H, Knutson KL, Gad E, Disis ML (2006) The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res 66:9754–9761PubMedCrossRef
22.
go back to reference Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177:1526–1533PubMed Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 177:1526–1533PubMed
23.
24.
25.
go back to reference Deetz CO, Hebbeler AM, Propp NA, Cairo C, Tikhonov I, Pauza CD (2006) Gamma interferon secretion by human Vgamma2 Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun 74:4505–4511PubMedCrossRef Deetz CO, Hebbeler AM, Propp NA, Cairo C, Tikhonov I, Pauza CD (2006) Gamma interferon secretion by human Vgamma2 Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun 74:4505–4511PubMedCrossRef
26.
go back to reference Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905–911. doi:10.1007/s00262-006-0248-1 PubMedCrossRef Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother 56:905–911. doi:10.​1007/​s00262-006-0248-1 PubMedCrossRef
27.
go back to reference Torisu M, Hayashi Y, Ishimitsu T et al (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31:261–268PubMedCrossRef Torisu M, Hayashi Y, Ishimitsu T et al (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31:261–268PubMedCrossRef
28.
go back to reference Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848PubMedCrossRef Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848PubMedCrossRef
30.
go back to reference Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E (2009) Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol 183:3625–3633. doi:10.4049/jimmunol.0901571 PubMedCrossRef Devilder MC, Allain S, Dousset C, Bonneville M, Scotet E (2009) Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol 183:3625–3633. doi:10.​4049/​jimmunol.​0901571 PubMedCrossRef
32.
go back to reference Nedellec S, Sabourin C, Bonneville M, Scotet E (2010) NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol 185:55–63. doi:10.4049/jimmunol.1000373 PubMedCrossRef Nedellec S, Sabourin C, Bonneville M, Scotet E (2010) NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol 185:55–63. doi:10.​4049/​jimmunol.​1000373 PubMedCrossRef
33.
go back to reference Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83–93PubMedCrossRef Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83–93PubMedCrossRef
34.
go back to reference Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737–1740PubMedCrossRef Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737–1740PubMedCrossRef
35.
go back to reference Hamerman JA, Ogasawara K, Lanier LL (2004) Cutting edge: toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol 172:2001–2005PubMed Hamerman JA, Ogasawara K, Lanier LL (2004) Cutting edge: toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol 172:2001–2005PubMed
36.
go back to reference Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR (2008) Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 181:6711–6719PubMed Kloss M, Decker P, Baltz KM, Baessler T, Jung G, Rammensee HG, Steinle A, Krusch M, Salih HR (2008) Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 181:6711–6719PubMed
37.
go back to reference Eissmann P, Evans JH, Mehrabi M, Rose EL, Nedvetzki S, Davis DM (2010) Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol 184:6901–6909. doi:10.4049/jimmunol.0903985 PubMedCrossRef Eissmann P, Evans JH, Mehrabi M, Rose EL, Nedvetzki S, Davis DM (2010) Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol 184:6901–6909. doi:10.​4049/​jimmunol.​0903985 PubMedCrossRef
40.
go back to reference Hedges JF, Lubick KJ, Jutila MA (2005) Gamma delta T cells respond directly to pathogen-associated molecular patterns. J Immunol 174:6045–6053PubMed Hedges JF, Lubick KJ, Jutila MA (2005) Gamma delta T cells respond directly to pathogen-associated molecular patterns. J Immunol 174:6045–6053PubMed
42.
go back to reference Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF (2003) Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 100:6009–6014PubMedCrossRef Kamath AB, Wang L, Das H, Li L, Reinhold VN, Bukowski JF (2003) Antigens in tea-beverage prime human Vgamma 2Vdelta 2 T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc Natl Acad Sci USA 100:6009–6014PubMedCrossRef
44.
go back to reference Graff JC, Kimmel EM, Freedman B, Schepetkin IA, Holderness J, Quinn MT, Jutila MA, Hedges JF (2009) Polysaccharides derived from Yamoa (Funtumia elastica) prime gammadelta T cells in vitro and enhance innate immune responses in vivo. Int Immunopharmacol 9:1313–1322. doi:10.1016/j.intimp.2009.07.015 PubMedCrossRef Graff JC, Kimmel EM, Freedman B, Schepetkin IA, Holderness J, Quinn MT, Jutila MA, Hedges JF (2009) Polysaccharides derived from Yamoa (Funtumia elastica) prime gammadelta T cells in vitro and enhance innate immune responses in vivo. Int Immunopharmacol 9:1313–1322. doi:10.​1016/​j.​intimp.​2009.​07.​015 PubMedCrossRef
45.
go back to reference Deng G, Lin H, Seidman A et al (2009) A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135:1215–1221. doi:10.1007/s00432-009-0562-z PubMedCrossRef Deng G, Lin H, Seidman A et al (2009) A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135:1215–1221. doi:10.​1007/​s00432-009-0562-z PubMedCrossRef
46.
go back to reference Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ (2012) Phase 1 clinical trial of trametes versicolor in women with breast cancer. ISRN Oncol 2012:251632. doi:10.5402/2012/251632 PubMed Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ (2012) Phase 1 clinical trial of trametes versicolor in women with breast cancer. ISRN Oncol 2012:251632. doi:10.​5402/​2012/​251632 PubMed
Metadata
Title
Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK
Authors
Carol Inatsuka
Yi Yang
Ekram Gad
Lauren Rastetter
Mary L. Disis
Hailing Lu
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 8/2013
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1436-4

Other articles of this Issue 8/2013

Cancer Immunology, Immunotherapy 8/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine